当前位置:药药网 / 数据中心 / 生物制药海外临床研究状况
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
标题(英文)
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
条件
Non-small Cell Lunch Cancer|Recurrent Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer
干预
Biological: Nivolumab|Biological: Relatlimab|Drug: Carboplatin|Drug: Cisplatin|Drug: Paclitaxel|Drug: Nab-Paclitaxel|Drug: Pemetrexed